If you've been using eye-whitening drops to brighten your eyes, you may want to stop.

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...

Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.

We tried out the popular Renpho Eyeris eye massager to see if it's worth the hype. Turns out, it is. Here's why.